Abbott has announced that it has reached a significant settlement agreement with DexCom, Inc., resolving all ongoing patent disputes between the two companies related to continuous glucose monitoring (CGM) products.
This settlement marks the conclusion of all current legal cases in courts and patent offices worldwide effectively bringing to an end a series of patent-related conflicts.
As part of the settlement, both Abbott (who make the FreeStyle Libre 2) and DexCom have agreed not to engage in any further litigation over patent, trade dress, or design rights for the next ten years.
This mutually agreed-upon resolution is seen as a step towards fostering greater collaboration in the diabetes technology space, allowing both companies to focus on advancing their respective solutions without the distraction of ongoing legal disputes.
Importantly, the settlement does not involve any financial payments between Abbott and DexCom.
The companies have opted to keep the specifics of the agreement confidential.
